MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure?

MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure?

Glaucoma is an optic nerve disease often linked to high eye pressure, but it involves many cellular stress pathways. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a tiny peptide made by mitochondria that helps cells cope with stress. Could it influence glaucoma progression or vulnerability beyond just controlling pressure? This article examines the mechanistic links between MOTS-c and glaucoma. We separate established facts from indirect clues and educated speculation. Every big claim is cited to the literature.

What MOTS-c Is

In 2015, researchers discovered MOTS-c – a 16-amino-acid peptide encoded in mitochondrial DNA (mtDNA) (translational-medicine.biomedcentral.com). It is produced from a short open reading frame in the mitochondrial 12S rRNA gene (translational-medicine.biomedcentral.com). MOTS-c levels rise in response to stress or exercise and decline with age (translational-medicine.biomedcentral.com). Under stress, MOTS-c moves from the mitochondria to the cell nucleus, where it helps activate antioxidant and stress-defense genes (translational-medicine.biomedcentral.com).

MOTS-c acts mainly through cellular energy sensors. It boosts the AMP-activated protein kinase (AMPK) pathway by diverting substrates toward AICAR production, mimicking a fasting/exercise signal (translational-medicine.biomedcentral.com) (translational-medicine.biomedcentral.com). AMPK is a key regulator of energy balance in cells. When AMPK is activated, it in turn can increase PGC-1α, a master regulator of mitochondrial function (translational-medicine.biomedcentral.com). Thus, MOTS-c indirectly drives cells to make more energy and repair mitochondria.

MOTS-c also influences inflammation and oxidative stress. In cell studies, treating stressed cells with MOTS-c increased AMPK and PGC-1α levels and lowered reactive oxygen species (ROS) and inflammatory signals (translational-medicine.biomedcentral.com). Specifically, MOTS-c reduced activation of NF-κB (a protein that drives inflammation) and cut levels of pro-inflammatory cytokines (like TNF-α, IL-1β, IL-6) while boosting anti-inflammatory IL-10 (translational-medicine.biomedcentral.com). It can also activate NRF2 pathways, which turn on antioxidant defenses (translational-medicine.biomedcentral.com) (translational-medicine.biomedcentral.com).

In simpler terms, MOTS-c is a stress-adaptive hormone made by mitochondria. It helps cells cope with metabolic and oxidative challenges by fueling energy production and calming inflammation (translational-medicine.biomedcentral.com) (translational-medicine.biomedcentral.com). It is being studied for benefits in diabetes, neurodegeneration, and aging-related conditions (translational-medicine.biomedcentral.com) (pmc.ncbi.nlm.nih.gov). However, its role in eye diseases (especially glaucoma) is not established.

Why Glaucoma Might Intersect with MOTS-c

Glaucoma damages the optic nerve and kills retinal ganglion cells (RGCs). Classic glaucoma causes are high intraocular pressure (IOP) and aging, but pressure-independent factors also play a major role. Key features of glaucoma biology may interact with what MOTS-c does:

• Retinal Ganglion Cell Energy Needs: RGCs have high metabolic demand. Their unmyelinated axons use many ATP-driven ion pumps and are packed with mitochondria (pmc.ncbi.nlm.nih.gov). These cells depend heavily on oxidative phosphorylation (OXPHOS) for energy (pmc.ncbi.nlm.nih.gov). If mitochondria falter, RGCs quickly suffer. In principle, MOTS-c’s ability to boost mitochondrial energy production could protect such high-demand neurons. (This is speculative: RGC-specific data on MOTS-c are lacking.)

• Mitochondrial Dysfunction in Glaucoma: A growing body of evidence implicates mitochondrial failure in glaucoma (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). For instance, glaucoma patients’ eye tissues and blood show signs of damaged mtDNA and reduced respiratory capacity (pmc.ncbi.nlm.nih.gov). Mouse and cell models of ocular hypertension reveal mitochondrial decline even before RGCs die (encyclopedia.pub) (pmc.ncbi.nlm.nih.gov). Because MOTS-c originates in mitochondria and signals their status, one could imagine it playing a role in this dysfunction. For example, if glaucoma stress reduces MOTS-c production or signaling, RGC stress responses could weaken. Conversely, adding MOTS-c might compensate by promoting healthier mitochondria via AMPK/PGC-1α.

• Oxidative Stress: Glaucoma involves oxidative damage in both the front eye (trabecular meshwork, affecting IOP) and back eye (optic nerve head) (encyclopedia.pub) (pmc.ncbi.nlm.nih.gov). High IOP and aging elevate ROS, harming RGCs (encyclopedia.pub) (pmc.ncbi.nlm.nih.gov). MOTS-c is known to trigger antioxidant defenses. It activates NRF2-linked gene expression and reduces ROS via AMPK–PGC1 pathways (translational-medicine.biomedcentral.com) (translational-medicine.biomedcentral.com). Thus, MOTS-c could directly counter oxidative stress in eye tissues. This link is hypothetical but plausible: a hypertension- or aging-induced rise in MOTS-c might help cells clear ROS.

• Neuroinflammation: Microglia and astrocytes become activated in glaucoma, releasing inflammatory cytokines and complement factors that damage RGCs (pmc.ncbi.nlm.nih.gov). In fact, inflammation is now recognized as a key early component of glaucomatous neurodegeneration (pmc.ncbi.nlm.nih.gov). MOTS-c has anti-inflammatory actions in other systems: it represses NF-κB and lowers inflammatory cytokines (translational-medicine.biomedcentral.com). It also shapes immune cells (e.g. promoting regulatory T cells via mTOR inhibition (pmc.ncbi.nlm.nih.gov)). By extension, if MOTS-c were active in the retina, it might dampen harmful neuroinflammation. Again, this is an inference: no study has tested MOTS-c on glial cells or retinal immune factors.

• Vascular/Ischemic Stress: Poor blood flow and fluctuating perfusion can accompany glaucoma, especially normal-tension glaucoma (NTG). High IOP can compress retinal blood vessels, causing transient ischemia and oxidative bursts (pmc.ncbi.nlm.nih.gov). Ischemia itself produces ROS and inflammatory signals. MOTS-c might help tissues adapt to ischemia by improving mitochondrial efficiency and reducing ROS (as seen in heart and muscle models). However, whether MOTS-c is induced by hypoxia or can cross into retinal tissue after systemic release remains unknown.

• Aging: Age is by far the strongest risk factor for glaucoma (pmc.ncbi.nlm.nih.gov). With aging, retinal mitochondria become less efficient and antioxidant defenses falter (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). MOTS-c levels normally decline with age (translational-medicine.biomedcentral.com). Thus, older individuals have less of this mitochondrial stress-messenger, possibly making RGCs more vulnerable. This suggests a pressure-independent decline of protective signals in glaucoma. (Inference: A drop in MOTS-c may partly explain age-related risk, but direct data are missing.)

• Normal-Tension vs. High-Pressure Glaucoma: In NTG, patients develop classic glaucoma damage without elevated IOP. This hints at metabolic, vascular, or genetic factors at play (pmc.ncbi.nlm.nih.gov). A mitochondrial signal like MOTS-c could hypothetically be more relevant in NTG, where pressure isn’t the sole driver. Conversely, in high-pressure glaucoma, damage might be dominated by mechanical stress and IOP, potentially limiting MOTS-c’s influence. This remains speculative; no data compare MOTS-c between NTG and other glaucoma types.

In summary, many glaucoma dangers (energy failure, oxidative stress, inflammation) align with known actions of MOTS-c (energy boosting, antioxidant, anti-inflammatory). This suggests a plausible intersection, but it is largely indirect inference.

What Direct Evidence Exists

So far, none. We found no published experiment directly linking MOTS-c to glaucoma or retinal ganglion cells. No study has measured MOTS-c in the eyes or blood of glaucoma patients, nor treated glaucoma models with MOTS-c. The one eye-related result is in retinal pigment epithelial (RPE) cells (relevant to macular degeneration). In that cell type, researchers saw that MOTS-c is present near mitochondria and protects RPE from oxidative stress (encyclopedia.pub). While encouraging, RPE are quite different from RGCs and not involved in glaucoma.

There is also no direct animal model work: for example, mice with experimental ocular hypertension have not been reported to receive MOTS-c supplementation or to have altered MOTS-c expression. Likewise, no cell-culture studies have tested MOTS-c on neurons or glia from the eye. In short, direct glaucoma-specific evidence is absent. All we have are educated guesses and analogies.

What Indirect Evidence Implies

Since direct data are missing, we turn to related fields:

• Metabolism and Stress: Multiple studies in non-ocular models show MOTS-c enhances stress resilience. For instance, in exercise and diabetes research, MOTS-c improved insulin sensitivity and protected tissues under metabolic stress (translational-medicine.biomedcentral.com) (pmc.ncbi.nlm.nih.gov). In a traumatic brain injury model, MOTS-c reduced oxidative damage and improved neurological outcomes. These reinforce that MOTS-c is broadly neuroprotective and antioxidant. By analogy, these effects could extend to retinal neurons.

• Age and Senescence: MOTS-c also counters aging-related decline. It has been shown to delay cellular senescence and improve survival in aged tissues. Given that aging links glaucoma with optic nerve susceptibility, loss of MOTS-c could be one piece of the puzzle. For example, if older retinas fail to produce enough MOTS-c under stress, they might lack a vital survival signal.

• Mitochondrial Disease Links: Some forms of glaucoma resemble mitochondrial DNA disorders (e.g. Leber’s hereditary optic neuropathy). In fact, shared mtDNA mutations are observed. MOTS-c belongs to a family of mitochondrial peptides (others include humanin) that showed protective effects in mitochondrial diseases. For example, humanin analogs protect RGCs in some models. This cluster of findings suggests mitochondrial signals matter in eye health.

• AMPK and SIRT1: Resveratrol (a SIRT1 activator) was reported to save RGCs in glaucoma models (encyclopedia.pub). MOTS-c likewise engages SIRT1 and AMPK in cells (translational-medicine.biomedcentral.com) (pmc.ncbi.nlm.nih.gov). This mechanistic similarity hints MOTS-c might mimic some of resveratrol’s benefits for RGCs. However, this is hypothetical: there is no study confirming MOTS-c‐SIRT1 interplay in retinal neurons.

Taken together, these adjacent findings support the idea that boosting mitochondrial adaptive responses could shield RGCs. They do not prove MOTS-c itself is critical in glaucoma, but they make it plausible. We emphasize: each step — from MOTS-c’s cell signals to glaucoma pathology — is supported by analogies, not glaucoma-specific tests.

A Systems-Level Hypothesis

We can sketch a conceptual network. Imagine MOTS-c as a node in the cell’s stress network:

• Upstream triggers: Cellular energy stress (low ATP, high AMP), exercise, calorie restriction, or oxidative damage all stimulate MOTS-c expression (translational-medicine.biomedcentral.com) (translational-medicine.biomedcentral.com). In glaucoma, factors like hypoxia or high ROS might trigger a MOTS-c response (though we don’t know if they do in the eye).

• MOTS-c node: When produced, MOTS-c moves to the nucleus. It interacts with transcription factors and signaling hubs: it raises AMPK, SIRT1, PGC-1α activity and activates NRF2, while inhibiting NF-κB and mTORC1 (translational-medicine.biomedcentral.com) (pmc.ncbi.nlm.nih.gov).

• Downstream effects: These changes enhance mitochondrial biogenesis, energy metabolism, and antioxidant defenses, while dialing down inflammation. In the retina, that could translate to better RGC survival, healthier glia, and stabilized blood flow regulation.

• Feedback loops: AMPK not only is activated by MOTS-c, but in turn helps shuttle MOTS-c into the nucleus (translational-medicine.biomedcentral.com), creating a positive loop. Aging or continuous stress might weaken this loop (less MOTS-c is made as cells get older (translational-medicine.biomedcentral.com)).

Where is evidence strong or weak? The fact that MOTS-c influences AMPK/PGC-1α and inflammation in other tissues is well-supported (translational-medicine.biomedcentral.com) (translational-medicine.biomedcentral.com). The existence of mitochondrial stress and oxidative damage in glaucoma is strongly documented (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The link that MOTS-c connects these two systems is hypothetical. We have no data on MOTS-c levels in retina or how glaucoma stimuli affect it (this is the big white box in the network).

In short, the model suggests: mitochondrial stress → MOTS-c increase → protective gene activation → RGC resilience. If any step fails (for instance, aging lowering MOTS-c output), injury can proceed. This is an appealing framework, but it has many gaps. It highlights where to focus experiments: mainly on sensing if and how MOTS-c operates in eye cells.

Counterarguments and Weak Points

Several reasons temper enthusiasm:

• Lack of Eye-Specific Data: All the glaucoma-MOTS-c connections above are inference or analogy. We must not overclaim. It is possible MOTS-c does nothing significant in the eye environment. For example, RPE findings don’t guarantee anything for RGCs.

• Delivery and Stability: MOTS-c is a small peptide. Like many peptides, it may be broken down quickly in the body and might not cross tissue barriers easily. There is no data on how long MOTS-c circulates or whether it reaches the retina at meaningful levels. Even if injected, it might degrade before helping RGCs. (No known pharmacokinetic studies address ocular delivery of MOTS-c.)

• Systemic vs Local: MOTS-c acts systemically (e.g. muscle-blood-liver). Glaucoma is a focal eye disease. It’s unclear if systemic MOTS-c influences the eye directly, or if local ocular cells produce and use their own MOTS-c. If the retina makes little MOTS-c itself, then relying on circulating MOTS-c could be ineffective.

• Glaucoma Heterogeneity: Glaucoma patients vary widely (age, blood pressure, genetics). Even if MOTS-c were beneficial, it might matter for only a subset of cases (perhaps those with metabolic syndrome or normal-tension glaucoma). It could be epiphenomenon in other cases where pressure damage dominates.

• Potential Side Effects: Boosting a pleiotropic signal has unknown effects. The wide action of MOTS-c (metabolism, immunity) means giving it systemically could have off-target impacts. This is a general concern for any drug, but worth noting.

• Reverse Causality: If we found low MOTS-c in glaucoma patients, is it cause or effect? Glaucoma (or treatment) might suppress MOTS-c production, rather than MOTS-c protecting against glaucoma. We must test causality.

• Rodent vs Human: Many MOTS-c studies are in mice or cell lines. Human glaucoma may differ. For instance, the 16-aa MOTS-c sequence is identical across mammals, but the control of its expression might not be.

In summary, while it is tempting to link MOTS-c and glaucoma via general biology, the lack of direct evidence is a major weakness. It could turn out to be a red herring.

What Should Be Tested Next

Given the intriguing hints, here are key experiments and studies to do:

• Measure MOTS-c in patients: Compare MOTS-c levels in blood, tear fluid, or aqueous humor from glaucoma patients and healthy controls. Subgroup analyses could check normal-tension versus high-pressure glaucoma. If glaucoma patients have chronically lower MOTS-c, that would motivate deeper study.

• Cell culture models: Expose cultured RGC neurons or retina explants to glaucoma-like stress (such as oxidative damage or pressure mimic) with and without MOTS-c. Does MOTS-c reduce cell death, ROS levels, or inflammatory markers? Conversely, does blocking AMPK/nefer effector abrogate the benefit?

• Animal glaucoma models: Induce ocular hypertension in rats or mice (e.g. microbead occlusion) and administer MOTS-c (systemically or intravitreally). Then measure RGC survival, optic nerve pathology, and visual function. A well-designed trial would have dose-response and timing, and possibly use both normal and aged animals.

• Retinal gene analysis: In animals or cell models, test if MOTS-c treatment changes expression of key protective genes (AMPK targets, antioxidant genes, mitochondrial biogenesis factors) in the retina or optic nerve head. Compare with known glaucoma stress signatures.

• Genetic models: If available, create mice that lack or overproduce MOTS-c (knockout of the mitochondrial ORF or transgenic overexpression) and see if they are more or less prone to glaucoma damage. This is a longer-term idea.

• Link with other risk factors: Study if metabolic syndrome or diabetes (where MOTS-c effects are known) alter glaucoma risk or progression, and whether MOTS-c correlates.

Each of these would help confirm or refute the hypothesis. They would clarify whether MOTS-c is a bystander marker or a functional player.

Conclusion

In conclusion, could MOTS-c matter in glaucoma? The answer is that we simply don’t know yet – there is no direct proof either way. On one hand, MOTS-c carries out many functions (AMPK/PGC1 activation, oxidative stress reduction, inflammation suppression) that theoretically align with needs for RGC survival. On the other hand, the evidence is all indirect and derived from other systems. Without targeted studies in eyes or glaucoma models, any assertion about MOTS-c’s role is a hypothesis, not a fact.

Thus, at present, MOTS-c is best viewed as a candidate signal that suggests mitochondria and metabolism deserve attention in glaucoma. It might be more useful as a clue pointing researchers toward broader mitochondrial interventions rather than a standalone therapy. Its strongest potential relevance is in pressure-independent (normal-tension) glaucoma or cases with metabolic risk factors, where traditional pressure-lowering treatments do not fully prevent optic nerve loss. But these ideas remain speculative.

Crucially, MOTS-c might turn out to be an epiphenomenon – something that changes during stress without controlling disease – or it might modestly modify the pace of ganglion cell loss. We cannot yet say if it is harmful, helpful, or neutral in glaucoma. For now, MOTS-c highlights the systems-level link between mitochondrial health and optic nerve resilience. The assumptions about its effects are biologically plausible but unproven.

The bottom line: Researchers should not assume MOTS-c is a silver bullet for glaucoma. However, it represents an intriguing intersection of metabolic signaling and neurodegeneration that merits careful testing.